ストックスクリーナーアプリを入手
190.06
2.29%
4.11
前日終値:
$185.95
開ける：
$189.305
24時間の取引高:
462.04K
Relative Volume:
0.37
時価総額：
$27.91B
収益：
$9.53B
当期純損益:
$1.29B
株価収益率:
21.58
EPS:
8.8057
ネットキャッシュフロー:
$1.97B
1週間 パフォーマンス:
+5.36%
1か月 パフォーマンス:
+4.82%
6か月 パフォーマンス:
+28.77%
1年 パフォーマンス:
+59.99%
1日の値動き範囲:
$188.67
$192.75
1週間の範囲:
$174.85
$192.75
52週間の値動き範囲:
$115.25
$202.41
Biogen Inc Stock (BIIB) Company Profile
Compare BIIB vs LLY, JNJ, ABBV, AZN, NVS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
190.18 | 27.29B | 9.53B | 1.29B | 1.97B | 8.8057 |
LLY
Lilly Eli Co
|
917.70 | 806.72B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
224.47 | 544.73B | 96.36B | 21.04B | 19.70B | 8.6488 |
ABBV
Abbvie Inc
|
202.90 | 362.81B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
195.88 | 303.62B | 58.80B | 10.24B | 8.98B | 3.2788 |
NVS
Novartis Ag Adr
|
147.25 | 282.35B | 54.72B | 14.02B | 15.32B | 7.1855 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-20 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2026-04-14 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2026-02-20 | 開始されました | Barclays | Equal Weight |
| 2026-02-09 | 繰り返されました | H.C. Wainwright | Buy |
| 2026-01-07 | 再開されました | UBS | Neutral |
| 2025-12-10 | ダウングレード | HSBC Securities | Hold → Reduce |
| 2025-11-06 | アップグレード | Stifel | Hold → Buy |
| 2025-09-25 | 開始されました | Jefferies | Buy |
| 2025-07-21 | 再開されました | Truist | Hold |
| 2025-04-28 | ダウングレード | HSBC Securities | Buy → Hold |
| 2025-04-04 | ダウングレード | Argus | Buy → Hold |
| 2025-02-11 | 開始されました | Bernstein | Mkt Perform |
| 2025-01-02 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | ダウングレード | Stifel | Buy → Hold |
| 2024-12-10 | 再開されました | BofA Securities | Neutral |
| 2024-12-09 | ダウングレード | Jefferies | Buy → Hold |
| 2024-11-18 | ダウングレード | Needham | Buy → Hold |
| 2024-11-15 | 開始されました | Wolfe Research | Peer Perform |
| 2024-11-14 | 開始されました | Citigroup | Neutral |
| 2024-10-31 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | 再開されました | Raymond James | Mkt Perform |
| 2024-02-14 | 繰り返されました | Needham | Buy |
| 2024-02-14 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | ダウングレード | UBS | Buy → Neutral |
| 2023-12-20 | 再開されました | Cantor Fitzgerald | Overweight |
| 2023-12-07 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | 開始されました | HSBC Securities | Buy |
| 2023-07-27 | 開始されました | Scotiabank | Sector Outperform |
| 2023-07-24 | 繰り返されました | UBS | Buy |
| 2023-05-01 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-04-17 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | アップグレード | Goldman | Neutral → Buy |
| 2022-10-13 | アップグレード | Stifel | Hold → Buy |
| 2022-10-07 | アップグレード | Argus | Hold → Buy |
| 2022-09-28 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | アップグレード | Mizuho | Neutral → Buy |
| 2022-09-28 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | ダウングレード | Stifel | Buy → Hold |
| 2022-03-03 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | 繰り返されました | Barclays | Equal Weight |
| 2022-02-04 | 繰り返されました | BofA Securities | Neutral |
| 2022-02-04 | 繰り返されました | Cowen | Outperform |
| 2022-02-04 | 繰り返されました | Morgan Stanley | Overweight |
| 2022-02-04 | 繰り返されました | Needham | Buy |
| 2022-02-04 | 繰り返されました | Oppenheimer | Outperform |
| 2022-02-04 | 繰り返されました | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | 繰り返されました | Robert W. Baird | Neutral |
| 2022-02-04 | 繰り返されました | Wedbush | Neutral |
| 2022-02-04 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-02-04 | 繰り返されました | Wolfe Research | Peer Perform |
| 2022-01-13 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-01-12 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | 再開されました | Raymond James | Mkt Perform |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-12-06 | 開始されました | Goldman | Neutral |
| 2021-11-19 | 開始されました | BMO Capital Markets | Outperform |
| 2021-09-23 | 開始されました | Needham | Buy |
| 2021-06-18 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | 繰り返されました | Truist | Buy |
| 2021-06-11 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | アップグレード | UBS | Neutral → Buy |
| 2021-06-08 | アップグレード | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | 繰り返されました | Barclays | Equal Weight |
| 2021-06-08 | アップグレード | Citigroup | Sell → Neutral |
| 2021-06-08 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-06-08 | 繰り返されました | Jefferies | Buy |
| 2021-06-08 | 繰り返されました | Morgan Stanley | Overweight |
| 2021-06-08 | 繰り返されました | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | アップグレード | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | 繰り返されました | Stifel | Buy |
| 2021-06-08 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | アップグレード | BofA Securities | Underperform → Neutral |
| 2021-06-07 | アップグレード | Cowen | Market Perform → Outperform |
| 2021-06-07 | アップグレード | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | ダウングレード | DZ Bank | Buy → Hold |
| 2021-01-29 | アップグレード | Stifel | Hold → Buy |
| 2020-11-10 | アップグレード | DZ Bank | Hold → Buy |
| 2020-11-09 | ダウングレード | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2020-11-09 | ダウングレード | Cowen | Outperform → Market Perform |
| 2020-11-09 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-11-04 | アップグレード | BofA Securities | Underperform → Neutral |
| 2020-11-04 | アップグレード | Jefferies | Hold → Buy |
| 2020-11-04 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | 開始されました | UBS | Neutral |
| 2020-07-27 | アップグレード | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2020-06-22 | 繰り返されました | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | ダウングレード | Citigroup | Neutral → Sell |
| 2020-04-23 | ダウングレード | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | 開始されました | Wolfe Research | Peer Perform |
| 2020-02-27 | 開始されました | Barclays | Overweight |
| 2020-01-27 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | ダウングレード | Robert W. Baird | Neutral → Underperform |
すべてを表示
Biogen Inc (BIIB) 最新ニュース
UBS Upgrades Biogen to Buy With a $225 Target: Are the Next 12 Months a Pipeline Catalyst Parade? - 24/7 Wall St.
BIIB Upgraded by UBS -- Price Target Raised to $225 - GuruFocus
Biogen boosts global pipeline with $100m TJ Biopharma deal - BioXconomy
Here Are Wednesday’s Top Wall Street Analyst Research Calls: Abbott Laboratories, Airbnb, Biogen, Cava Group, GitLab, Halliburton, Qualcomm, Seagate, Toast, and More - Yahoo Finance
UBS Upgrades Biogen to Buy From Neutral, Adjusts Price Target to $225 From $185 - marketscreener.com
Analyst recommendations: Albemarle, Biogen, Qualcomm, Twilio, Lyondellbasell… - marketscreener.com
TJ Biopharma enters into agreement with Biogen for Felzartamab assets in Greater China Region - BioSpectrum Asia
UBS upgrades Biogen stock rating on pipeline catalysts, raises target to $225 - Investing.com
Stocks making big moves yesterday: Cadence Design Systems, JFrog, Lucid, Ulta, and Biogen - Yahoo Finance
Biogen Inc. Secures Global Rights To Felzartamab Through Greater China Deal With TJ Biopharma - BioPharma APAC
Biogen amasses full felzartamab rights with $850M TJ deal - BioWorld News
BIIB Inks Deal to Acquire Rights to Felzartamab in China, Stock Up - TradingView
3 Reasons to Avoid BIIB and 1 Stock to Buy Instead - Yahoo Finance
Amyloid Setback: Future Possibilities For The Treatment Of Alzheimer's Disease - Seeking Alpha
Biogen gets worldwide development and commercialization rights to felzartamab - The Pharma Letter
Lobbying Update: $1,460,000 of BIOGEN lobbying was just disclosed - Quiver Quantitative
Biogen (BIIB) Stock Trades Up, Here Is Why - Yahoo Finance
Biogen Inc (BIIB) Shares Surge 3.4% -- What GF Score of 72 Tells Investors - GuruFocus
Biogen Inc. stock (US09062X1037): Is its neurology focus strong enough to drive new upside? - AD HOC NEWS
Biogen earnings preview: What to expect - MSN
Biogen (BIIB) Secures Exclusive Rights to Felzartamab in Greater China - GuruFocus
BIIB Upgraded by Wells Fargo -- Price Target Raised to $250 - GuruFocus
Biogen Earnings Preview: What to Expect - Barchart.com
Biogen to buy China rights to immune disease drug for up to $850M - Seeking Alpha
Wells Fargo Upgrades Biogen to Overweight: Does the Alzheimer's Story Finally Have a Second Act? - 24/7 Wall St.
Biogen buys China rights to immune disease drug in up to $850 million deal with TJ Biopharma - Reuters
TJ Biopharma Enters into Agreement with Biogen for Felzartamab Assets in the Greater China Region - Tirto.id
Biogen enters into agreement with TJ Biopharma for Felzartamab assets in the Greater China region - marketscreener.com
Biogen acquires China rights to felzartamab for up to $850M By Investing.com - Investing.com Canada
Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region - Biogen
Biogen Enters Into Agreement With TJ Biopharma For Felzartamab Assets In The Greater China Region - marketscreener.com
Wells Fargo Upgrades Biogen to Overweight From Equalweight, Adjusts PT to $250 From $200 - marketscreener.com
Biogen Expands Targeted Therapy Pipeline With Apellis Deal And Alloy Alliance - Yahoo Finance
Biogen Inc. (NASDAQ:BIIB) Rating Balance Draws Nasdaq Composite Attention - Kalkine Media
Notable analyst calls this week: Tesla, Qualcomm and Biogen among top picks - Seeking Alpha
Understanding Momentum Shifts in (BIIB) - Stock Traders Daily
Biogen Inc. (NASDAQ:BIIB) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Biogen secures FDA nod for higher dose of SMA drug Spinraza - MSN
Should Value Investors Buy Biogen (BIIB) Stock? - Yahoo Finance
Biogen CEO: China will match U.S. drug innovation in five to 10 years - The Business Journals
Zacks.com featured highlights include Biogen, TE Connectivity and ZTO Express (Cayman) - The Globe and Mail
Biogen Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Bulls and Biogen Team Up to Celebrate "America 250" with Triangle Community - MLB.com
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’ - BioWorld News
'There's a lot of momentum': Biogen acquisition translates into West Coast hub with immunology focus - The Business Journals
US FDA's accelerated approval for drugs needs more transparency, says research firm - marketscreener.com
How Biogen’s Alloy ASO Deal Could Shape Its Neurology Pipeline Will Impact Biogen (BIIB) Investors - simplywall.st
This Healthcare Stock Has Made Long-Term Investors Rich -- Can It Keep Doing It? - The Motley Fool
Sumitomo Mitsui Trust Group Inc. Lowers Holdings in Biogen Inc. $BIIB - MarketBeat
Biogen (BIIB) Valuation Check After Mixed Recent Returns And Growing Focus On LEQEMBI Growth Potential - Yahoo Finance
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
Biogen Inc (BIIB) 財務データ
収益
当期純利益
現金流量
EPS
2.07%
0.25%
大文字化:
|
ボリューム (24 時間):